Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

NANOBODY®(a registered trademark of Ablynx NV) molecules (Nbs), also referred to as
single domain-based VHHs, are antibody fragments derived from heavy-chain only IgG …

Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells
in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal …

Highlights•Nanobodies (Nbs) are camelid-derived single-domain antibodies.•Nbs have
powerful binding and inhibitory capacity with great therapeutic potential.•Nbs are used in …

Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with
many unique properties such as small size, excellent solubility, superior stability, quick …

Since the serendipitous discovery 20 years ago of bona fide camelid heavy-chain
antibodies, their single-domain antigen-binding fragments, known as VHHs or nanobodies …

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs)
have been presented as a class of non‐invasive nanomaterials for numerous biomedical …

The unique class of heavy chain–only antibodies, present in Camelidae, can be shrunk to
just the variable region of the heavy chain to yield VHHs, also called nanobodies. About one …

The development of tumor-targeted therapies using monoclonal antibodies has been
successful during the last 30 years. Nevertheless, the efficacy of antibody-based therapy is …

Antibodies are important tools for experimental research and medical applications. Most
antibodies are composed of two heavy and two light chains. Both chains contribute to the …